Given the most recent publication in JAMA Oncology linked below, in cancer patients who develop severe immune checkpoint inhibitor induced dermatitis, do you or will you consider short-term oral upadacitinib as a steroid-sparing agent to rapidly resolve rash and pruritus without compromising oncology outcomes?

Given the risk of thrombosis, which is already elevated in many malignancies, and knowing that suppression of Th1 activity makes it harder to fight cancer, I would avoid JAKi. IL-31 may be safer for pruritus, along with topical steroids for rash.

Given reports such as this one and the one cited below, it is evident that many of the AEs associated with PD-1 inhibitors are induced by cytokine over-stimulation. Dependent on the condition, either a biologic (TNF inhibitor, IL-17 inhibitor, or IL-23 inhibitor) or a JAK inhibitor is certainly wort...